BACKGROUND: In resource-limited settings, HIV-1 drug resistance testing to guide antiretroviral therapy (ART) selection is unavailable. We retrospectively conducted genotypic analysis on archived samples from Nigerian patients who received targeted viral load testing to confirm treatment failure and report their drug resistance mutation patterns. METHODS: Stored plasma from 349 adult patients on non-nucleoside reverse transcriptase inhibitor (NNRTI) regimens was assayed for HIV-1 RNA viral load, and samples with more than 1000 copies/ml were sequenced in the pol gene. Analysis for resistance mutations utilized the IAS-US 2011 Drug Resistance Mutation list. RESULTS: One hundred and seventy-five samples were genotyped; the majority of the subtypes were G (42.9%) and CRF02_AG (33.7%). Patients were on ART for a median of 27 months. 90% had the M184V/I mutation, 62% had at least one thymidine analog mutation, and 14% had the K65R mutation. 97% had an NNRTI resistance mutation and 47% had at least two etravirine-associated mutations. In multivariate analysis tenofovir-based regimens were less likely to have at least three nucleoside reverse transcriptase inhibitor (NRTI) mutations after adjusting for subtype, previous ART, CD4, and HIV viral load [P < 0.001, odds ratio (OR) 0.04]. 70% of patients on tenofovir-based regimens had at least two susceptible NRTIs to include in a second-line regimen compared with 40% on zidovudine-based regimens (P = 0.04, OR = 3.4). CONCLUSIONS: At recognition of treatment failure, patients on tenofovir-based first-line regimens had fewer NRTI drug-resistant mutations and more active NRTI drugs available for second-line regimens. These findings can inform strategies for ART regimen sequencing to optimize long-term HIV treatment outcomes in low-resource settings.
BACKGROUND: In resource-limited settings, HIV-1 drug resistance testing to guide antiretroviral therapy (ART) selection is unavailable. We retrospectively conducted genotypic analysis on archived samples from Nigerian patients who received targeted viral load testing to confirm treatment failure and report their drug resistance mutation patterns. METHODS: Stored plasma from 349 adult patients on non-nucleoside reverse transcriptase inhibitor (NNRTI) regimens was assayed for HIV-1 RNA viral load, and samples with more than 1000 copies/ml were sequenced in the pol gene. Analysis for resistance mutations utilized the IAS-US 2011 Drug Resistance Mutation list. RESULTS: One hundred and seventy-five samples were genotyped; the majority of the subtypes were G (42.9%) and CRF02_AG (33.7%). Patients were on ART for a median of 27 months. 90% had the M184V/I mutation, 62% had at least one thymidine analog mutation, and 14% had the K65R mutation. 97% had an NNRTI resistance mutation and 47% had at least two etravirine-associated mutations. In multivariate analysis tenofovir-based regimens were less likely to have at least three nucleoside reverse transcriptase inhibitor (NRTI) mutations after adjusting for subtype, previous ART, CD4, and HIV viral load [P < 0.001, odds ratio (OR) 0.04]. 70% of patients on tenofovir-based regimens had at least two susceptible NRTIs to include in a second-line regimen compared with 40% on zidovudine-based regimens (P = 0.04, OR = 3.4). CONCLUSIONS: At recognition of treatment failure, patients on tenofovir-based first-line regimens had fewer NRTI drug-resistant mutations and more active NRTI drugs available for second-line regimens. These findings can inform strategies for ART regimen sequencing to optimize long-term HIV treatment outcomes in low-resource settings.
Authors: Jibreel Jumare; Nicaise Ndembi; Samer S El-Kamary; Laurence Magder; Laura Hungerford; Tricia Burdo; Lindsay M Eyzaguirre; Patrick Dakum; Anya Umlauf; Mariana Cherner; Alash'le Abimiku; Man Charurat; William A Blattner; Walter Royal Journal: Clin Infect Dis Date: 2018-04-17 Impact factor: 9.079
Authors: Yuruo Li; Hongjie Liu; Habib O Ramadhani; Nicaise Ndembi; Trevor A Crowell; Gustavo Kijak; Merlin L Robb; Julie A Ake; Afoke Kokogho; Rebecca G Nowak; Charlotte Gaydos; Stefan D Baral; Erik Volz; Sodsai Tovanabutra; Man Charurat Journal: AIDS Date: 2020-02-01 Impact factor: 4.632
Authors: Lindiwe Skhosana; Kim Steegen; Michelle Bronze; Azwidowi Lukhwareni; Esrom Letsoalo; Maria A Papathanasopoulos; Sergio C Carmona; Wendy S Stevens Journal: PLoS One Date: 2015-02-06 Impact factor: 3.240
Authors: Mark M Manak; Ogbonnaya S Njoku; Ashley Shutt; Jennifer Malia; Linda L Jagodzinski; Mark Milazzo; Aminu Suleiman; Amos A Ogundeji; Robert Nelson; Ojor R Ayemoba; Robert J O'Connell; Darrell E Singer; Nelson L Michael; Sheila A Peel Journal: J Clin Microbiol Date: 2015-08-26 Impact factor: 5.948
Authors: Ragna S Boerma; T Sonia Boender; Kim C E Sigaloff; Tobias F Rinke de Wit; Michael Boele van Hensbroek; Nicaise Ndembi; Titilope Adeyemo; Edamisan O Temiye; Akin Osibogun; Pascale Ondoa; Job C Calis; Alani Sulaimon Akanmu Journal: J Int AIDS Soc Date: 2016-11-10 Impact factor: 5.396